NCT04999176 (VALERIA) is a Phase 3 clinical trial of Rivaroxaban in Cancer, sponsored by André Luiz Malavasi Longo de Oliveira.

Who is sponsoring NCT04999176?

NCT04999176 is sponsored by André Luiz Malavasi Longo de Oliveira.

What drugs are being tested in NCT04999176?

Interventions in NCT04999176: Rivaroxaban, Enoxaparin.

What condition does NCT04999176 study?

NCT04999176 studies Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis.

Is NCT04999176 still recruiting?

NCT04999176 is currently status unknown. Last updated 10 August 2021.

Last reviewed 2021-08-10 · How we verify

NCT04999176: VALERIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin

Status unknown Phase 3 Last updated 10 August 2021

What this trial tests

Phase 3 trial testing Rivaroxaban in Cancer in 440 participants. Status unknown.

Timeline

22 October 2020

Primary endpoint
15 July 2024

15 July 2024

Quick facts

Lead sponsor	André Luiz Malavasi Longo de Oliveira
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	440
Start date	22 October 2020
Primary completion	15 July 2024
Estimated completion	15 July 2024
Sites	1 location across Brazil

Drugs / interventions tested

Rivaroxaban (rivaroxaban) — full drug profile →
Enoxaparin — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →
Rivaroxaban — all drugs for Rivaroxaban →
Venous Thromboembolism — all drugs for Venous Thromboembolism →
Thromboprophylaxis — all drugs for Thromboprophylaxis →

Sponsor

André Luiz Malavasi Longo de Oliveira

Who can join

Adults 18 to 89, female only, with Cancer or Rivaroxaban. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA tr
Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, et al · · 2022 · cited 23× · PMID 36474344 · DOI 10.1177/10760296221132556

Verify or expand the search:

Other trials of Rivaroxaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04999176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by André Luiz Malavasi Longo de Oliveira
Last refreshed: 10 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing